Urinary Tract Tissue Articles & Analysis: Older

4 news found

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

APPROVED USE FOR JELMYTO JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC). ...

Feb. 10, 2022

ByUroGen Pharma, Inc.

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. ...

Feb. 3, 2022

ByUroGen Pharma, Inc.

UroGen Pharma to Present at Upcoming Conferences

Jan. 5, 2022

ByUroGen Pharma, Inc.

First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

Dec. 21, 2021

ByUroGen Pharma, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you